BorghaeiH,LynchTJ,RizviNA, 2013.A phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/ metastatic nonsquamous non-small-cell lung cancer (NSCLC),J Clin Oncol 31 TPS8121 -
DominguesD,TurnerA,SilvaMD, 2014.Immunotherapy and lung cancer: current developments and novel targeted therapies,Immunotherapy 6 1221 -35
RizviNA,MazieresJ,PlanchardD, 2015.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial,Lancet Oncol 16 257 -65
BrahmerJ,ReckampKL,BaasP, 2015.Nivolumab versus docetaxel in advanced squamous non-small cell lung cancer,N Engl J Med 373 123 -35
KazandjianD,KhozinS,BlumenthalG, 2016.Benefit-risk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy a report from the US food and drug administration,JAMA Oncol 2 118 -22